- Surmodics' SurVeil™ DCB demonstrates comparable safety and efficacy to IN.PACT™ Admiral™ DCB with a 75% lower paclitaxel dose.
- TRANSCEND trial enrolled 446 patients across 65 sites in 9 countries, showing 82.2% vs. 85.9% primary patency at 12 months.
- Surmodics (SRDX, Financial) completed a 5-year follow-up data collection for its SurVeil DCB in 2024.
Surmodics, Inc. (SRDX) has announced the publication of the TRANSCEND clinical trial results, which demonstrate that the SurVeil™ drug-coated balloon (DCB) is non-inferior in safety and efficacy to the IN.PACT™ Admiral™ DCB for treating patients with femoropopliteal arterial disease, despite using 75% less paclitaxel—a key anti-proliferative drug. The findings, published in the March 2025 edition of the European Journal of Vascular and Endovascular Surgery, indicate comparable outcomes in both primary patency and safety endpoints at 12 months.
The global, randomized TRANSCEND study included 446 patients from 65 sites across nine countries, with 222 patients treated with the SurVeil DCB and 224 with the IN.PACT Admiral DCB. The primary efficacy endpoint showed a 12-month primary patency rate of 82.2% for the SurVeil DCB compared to 85.9% for the IN.PACT Admiral DCB. Additionally, the safety endpoint was 91.8% for SurVeil DCB versus 89.9% for IN.PACT Admiral DCB.
Both devices employ paclitaxel-coated balloons to treat superficial femoral and proximal popliteal artery lesions, but the SurVeil DCB uses a significantly lower drug load of 2.0 µg/mm² compared to the 3.5 µg/mm² used by IN.PACT Admiral. Surmodics highlights the advanced technology and uniform microcrystalline coating of the SurVeil DCB, which is designed to optimize drug delivery and retain a strong therapeutic effect.
The 5-year follow-up data collection, completed in 2024, reflects Surmodics' commitment to advancing medical device technology and supporting physician decision-making in treating peripheral artery disease, which affects more than 100 million people worldwide.
